New target in combinatorial breast cancer treatment
Targeted precision medicine in combination with companion diagnostics (a diagnostic test to determine the applicability of the therapeutic drug to a specific person) represents an attractive option for effective patient care. Recent advances in breast cancer treatment using a combination of targets are at the forefront of this development. The recently discovered Nudix-linked to moiety X-5 enzyme (NUDIX5) plays a role in adenosine triphosphate generation in the nucleus. Overexpression of the NUDIX5 in breast and other types of cancer has been associated with a poor prognosis and increased risk of recurrence and metastasis. The EU-funded IMPACCT project proposes to determine if the developed NUDIX5 inhibitors, in combination with companion diagnostics, can be used as a targeted treatment in breast cancer patients.
Fields of science
Call for proposalSee other projects for this call
Funding SchemeERC-POC - Proof of Concept Grant
See on map
See on map